Q2FY23 Financial Summary and Strategic Highlights

Leading ESG practices grounded in our Mission Focused sustainability areas and targets Top Priorities Emerging Priorities • Additional Priorities . • Innovation & access Patient safety & product quality • Inclusion, diversity & equity Climate risk & resilience Responsible supply mgmt Product stewardship Transparency ⚫ Integrated Care • • • Technology & Device Security Data privacy & security Ethics in sales & marketing Corruption & bribery Affordability & fair pricing Talent Good citizenship Patient Safety & Product Quality 10% Reduction in aggregate product complaint rate for identified product families by FY25 vs. FY20 Access & Innovation 20% MDT revenue from products and therapies released in the prior 36 months by FY25 85M Patients served annually by FY25 ESG targets Inclusion, Diversity & Equity 45% Global management positions held by women by FY26 30% U.S. management positions held by ethnically diverse talent by FY26 Climate Stewardship 50% Reduction in greenhouse gas emission intensity by FY25 vs. FY20 50% Sourced energy from renewable and alternative sources by FY25 vs. FY20 Carbon Neutral In our operations by FY30 Net Zero Emissions By 2045 Product Stewardship 25% Reduction in packaging waste for targeted high- volume products by FY25 vs. FY21 35% Reduction in paper associated Instructions for Use (IFUs) by FY27 vs. FY21 17 Investor Meetings | November 2022 Medtronic

View entire presentation